07:00 , Jul 20, 2009 |  BC Week In Review  |  Company News

Cancer Innovations Inc., Eisai deal

Eisai's Morphotek Inc. subsidiary received an option for exclusive, worldwide rights to Cancer Innovations' undisclosed mAbs targeting tumor-associated proteins. Morphotek has an undisclosed period to evaluate the mAbs. Further terms were not disclosed. Cancer Innovations...